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Abstract
Objectives: DMBT is an antibacterial pattern recognition and scavenger receptor. In this study, we analyzed the role of
DMBT1 single nucleotide polymorphisms (SNPs) regarding inflammatory bowel disease (IBD) susceptibility and examined
their functional impact on transcription factor binding and downstream gene expression.
Methods: Seven SNPs in the DMBT1 gene region were analyzed in 2073 individuals including 818 Crohn’s disease (CD)
patients and 972 healthy controls in two independent case-control panels. Comprehensive epistasis analyses for the known
CD susceptibility genes NOD2, IL23R and IL27 were performed. The influence of IL23R variants on DMBT1 expression was
analyzed. Functional analysis included siRNA transfection, quantitative PCR, western blot, electrophoretic mobility shift and
luciferase assays.
Results: IL-22 induces DMBT1 protein expression in intestinal epithelial cells dependent on STAT3, ATF-2 and CREB1. IL-22
expression-modulating, CD risk-associated IL23R variants influence DMBT1 expression in CD patients and DMBT1 levels are
increased in the inflamed intestinal mucosa of CD patients. Several DMBT1 SNPs were associated with CD susceptibility. SNP
rs2981804 was most strongly associated with CD in the combined panel (p = 3.061027, OR 1.42; 95% CI 1.24–1.63). All
haplotype groups tested showed highly significant associations with CD (including omnibus P-values as low as 6.1610218).
The most strongly CD risk-associated, non-coding DMBT1 SNP rs2981804 modifies the DNA binding sites for the
transcription factors CREB1 and ATF-2 and the respective genomic region comprising rs2981804 is able to act as a
transcriptional regulator in vitro. Intestinal DMBT1 expression is decreased in CD patients carrying the rs2981804 CD risk
allele.
Conclusion: We identified novel associations of DMBT1 variants with CD susceptibility and discovered a novel functional
role of rs2981804 in regulating DMBT1 expression. Our data suggest an important role of DMBT1 in CD pathogenesis.
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Introduction
The pathogenesis of the inflammatory bowel diseases (IBD)
Crohn’s disease (CD) and ulcerative colitis (UC) is not completely
understood. Current models of disease pathogenesis suggest that
IBD is caused by a complex interplay of environmental factors
such as the microbiota of the host, the host immune system and
genetic predisposition. The first IBD susceptibility gene NOD2/
CARD15 (which is particularly associated with small intestinal
disease), was identified in 2001 and encodes an intracellular
bacterial pattern recognition receptor (PRR) [1,2]. Since then,
emerging evidence suggests that particularly autophagy genes such
as ATG16L1 [3,4] and IRGM [5,6] as well as genes involved in the
proinflammatory Th17 cell pathway such as IL23R, IL12B, JAK2,
STAT3, CCR6, and IL2/IL21 [7,8,9,10] are associated with CD.
DMBT1, a glycoprotein of the scavenger receptor cystein-rich
(SRCR) family, is a protein participating in antibacterial host
defense on mucosal surfaces such as the intestine or the oral mucosa.
It acts as a PRR that recognizes leucine-rich repeats of bacterial
proteins [11]. It is known that DMBT1 inhibits NF-kB activation
induced by the bacterial products lipopolysaccharide (LPS) and
muramyldipeptide (MDP) [12], aggregates group A Streptococci by
binding pili [13], and inhibits Salmonella enterica cytoinvasion [12],
resulting in reduced bacterial adhesion to human epithelial cells
[13,14,15,16]. Interestingly, DMBT1 is a target gene of NOD2 [12]
and also a target of TLR4 for which we and others demonstrated
associations with IBD susceptibility [17,18].
Studies with experimental dextran sulfate sodium (DSS) colitis
models in DMBT1 knockout (KO) mice had heterogeneous
outcomes. While in one study, no difference between KO and
wild-type (WT) mice was observed [19], another study reported
enhanced susceptibility to DSS colitis in KO mice [20] whereas a
third study observed differences only at low doses of DSS [16].
However, to what extent these findings can be directly transferred
to human IBD, remains to be determined. The contradictory
results may reflect a general problem in using mouse models for
human intestinal inflammation as it has been demonstrated
recently that some mouse models of inflammation poorly mimic
the more complex human conditions [21].
In humans, it has been demonstrated that DMBT expression is
upregulated by proinflammatory stimuli such as TNF-a or LPS
[12] and correlates with disease activity in IBD patients [20,22].
Recently, a copy number polymorphism in DMBT1, resulting in a
substantially decreased number of scavenger receptor cysteine-rich
(SRCR) domains, was identified as a risk factor for CD [20].
In this study, we aimed to further clarify the role of DMBT1 in
intestinal epithelial cells (IEC) and in the pathogenesis of IBD. We
investigated the IL-22-mediated transcriptional regulation of
DMBT1 in the IEC lines HT-29 and DLD-1 and analyzed the
influence of IL-22 expression-modulating, CD-associated IL23R
variants on DMBT1 expression in biopsies from CD patients.
Moreover, we analyzed seven DMBT1 gene variants and their
haplotypes, including four so far not analyzed single nucleotide
polymorphisms (SNPs) in a large panel of 2073 Caucasian
individuals regarding their association with IBD risk and disease
phenotype. We tested for gene-gene interaction (epistasis) of
DMBT1 variants with known CD susceptibility variants in NOD2,
IL23R and IL27 since previous studies demonstrated that these
genes may also be involved in the modulation of DMBT1
expression [12,23,24]. In addition, we analyzed the functional
impact of variants in DMBT1 on transcription factor binding to
the respective DNA and the downstream gene expression and
identified a CD-associated DMBT1 variant that is linked to the
colonic DMBT1 gene expression in CD patients.
Patients and Methods
Ethics Statement
The study was approved by the Ethics committee of the Medical
Faculty of the Ludwig-Maximilians-University Munich. Written,
informed consent was obtained from all patients prior to the study.
Study protocols were based on the ethical principles for medical
research involving human subjects of the Helsinki Declaration
(http://www.wma.net/e/policy/b3.htm).
Reagents and Antibodies
Human recombinant IL-22 was obtained from R&D Systems
(Wiesbaden, Germany). Antibodies against CREB1 and ATF-2
were from Santa Cruz Biotechnology (Heidelberg, Germany) and
p84 antibody was from Abcam (Cambridge, UK). The secondary
anti-rabbit antibody was from GEHealthcare (Freiburg, Germany).
RNA Isolation, Reverse Transcription and Quantitative
PCR
Total RNA from IEC was isolated using the RNeasy Mini Kit
from Qiagen (Hilden, Germany) and 500 ng were reverse
transcribed using the Transcriptor First Strand cDNA Synthesis
Kit from Roche (Mannheim, Germany). Total RNA from
intestinal biopsies was isolated using a Branson sonifier to disrupt
the tissue followed by RNA extraction with Trizol reagent and
chloroform. Quantitative real-time PCR was performed as
previously described [23] using a LightCycler 480 instrument
(Roche Diagnostics, Mannheim, Germany) and SYBR green
detection format. Gene expression was normalized to the b-actin
expression in the respective samples. The following primers were
used for quantification: CREB1 forward 59-CACAGATTGCCA-
CATTAGCC-39, CREB1 reverse 59-TGAACTGTTTGGA-
CTTGTGGAG-39, ATF-2 forward 59-GTCATGGTAGCG-
GATTGGTT-39, ATF-2 reverse 59-CTTCTCCGACGAC-
CACTTGT-39, DMBT1 forward 59-TGCTCTGTCTGCCA-
AATCAC-39, DMBT1 reverse 59-GTCATTGTCTGCCTGC-
TTGA-39, b-actin forward 59-CCTCGCCTTTGCCGAT-
CCGC-39, b-actin reverse 59-CCACCATCACGCCCTGGT-
GC-39.
Western Blot
Western Blot analysis was performed according to standard
procedures [25] with nuclear extracts isolated from IEC lines as
described [23]. Briefly, 20 mg of nuclear extract or 50 mg of total
protein were separated on an 8–16% gradient polyacrylamide gel
and were transferred to a PVDF membrane. Membranes were
blocked with 5% milk in TBS-T and incubated with the primary
antibody overnight at 4uC. Following incubation with the
secondary HRP-coupled antibody, luminescent detection was
performed with the ECL system (Pierce) and a CCD camera
(Peqlab, Erlangen, Germany).
siRNA Transfection
DLD-1 cells were reverse transfected in 24 well plates (for RNA
isolation) or 10 cm plates (for nuclear extract isolation) with siRNA
(Life Technologies, Darmstadt, Germany) using Lipofectamine
RNAiMAX (Life Technologies) following the manufacturer’s
guidelines. Total mRNA and nuclear protein was isolated and
specific knockdown was assessed by quantitative PCR and
Western Blot, respectively.
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In silico Analysis of Transcription Factor Binding Sites
Genomic sequences including SNPs rs2981745 and rs2981804
were analyzed for potential transcription factor binding sites of
human transcription factors with the TFSEARCH program
(http://www.cbrc.jp/research/db/TFSEARCH.html) which is
based on the TRANSFAC database [26]. The threshold score
for binding site prediction was set to 75.0 (score = 100.0*(‘weighted
sum’2min)/(max2min); max. score = 100). For each SNP, both
alleles including the flanking sequences 10 bp upstream and
downstream were compared.
Nuclear Extracts and Electrophoretic Mobility Shift Assay
(EMSA)
Isolation of nuclear extracts from IEC lines HT-29, DLD-1,
HCT116 and SW480 was performed according to standard
procedures [27] with minor modifications [23]. EMSA analysis
was performed essentially as described [23]. Briefly, 100 fmol of
biotinylated, double-stranded probes were incubated with 5 mg of
nuclear extract from cell lines as indicated in the presence of 1 mg
of poly d(I)-d(C) for 30 min. Where indicated, 1 mg of anti-CREB1
or anti-ATF-2 antibody or a non-specific negative control
antibody was added. For competition experiments, 50-fold molar
excess of unlabelled probe was included in the reaction before
adding the labelled probe. Samples were separated on a 6%
polyacrylamide gel (2.5 hours at 100 V for the DMBT1 probe, 1.5
hours for the CREB1 probe) and were transferred to a positively
charged nylon membrane. Detection of biotinylated probes was
performed with streptavidin-HRP using the LightShift Chemilu-
minescent EMSA kit from Pierce (Thermo Fisher Scientific, Bonn,
Germany). The sequences of the two different DMBT1 probes
used were 59-CCTGCTAACGTAACCAAATTGCTA-39 and 59-
CCTGCTAACGTAGCCAAATTGCTA-39. The sense orienta-
tion for each probe is given and the polymorphic nucleotide
comprising DMBT1 SNP rs2981804 is underlined. The sequence
for the CREB1 probe was 59-AGAGATTGCCTGACGTCAGA-
GAGCTAG-39 and the sequence for the ATF-2 probe was 59-
CTTAGTTACGTAATAATTGT-39 (consensus sequence under-
lined). The unspecific competitor probe had the sequence
59-GATCCTTCTGGGCCGTCCTAGATC-39.
Plasmid Cloning, Transient Transfection and Luciferase
Assay
The genomic region harboring SNP rs2981804 was amplified
by PCR from HT-29 cells (genotype AA) or DLD1 cells (genotype
GG). The resulting fragments were cloned either into the
luciferase reporter plasmid pGL4.23 (Promega, Mannheim,
Germany) which contains a minimal promoter (minP) in front of
the luciferase gene resulting in low basal expression or into the
pGL4.13 vector with a strong SV40 promoter/enhancer with high
basal expression. For both vector backbones, three constructs were
cloned: 1) DMBT1 insert upstream, i.e. 59 of the promoter into the
multiple cloning site, 2) DMBT1 insert 2 kb downstream, i.e. 39 of
the promoter, and 3) DMBT1 insert 39 and 59 of the promoter. All
constructs were verified by sequencing.
DLD1 or HT-29 cells were transfected in 96-well plates with 100
or 200 ng of plasmid, respectively, using Lipofectamine LTX (Life
Technologies), together with 10 or 20 ng of Renilla luciferase
plasmid. After 24 hours, luciferase activity was detected using the
Dual-Glo Luciferase Assay System (Promega). Relative light units
(RLU) were normalized to the levels of Renilla luciferase. A detailed
description of all experimental cloning procedures and the primers
used can be found in the methods S1, figures S1 and S2 and table S1.
Study Population
The study population (n= 2073) consisted of 818 Crohn’s
disease (CD) patients and 972 healthy, unrelated controls [(623
CD patients and 762 controls in the discovery panel (recruited
from the IBD center of the University Hospital Munich-
Grosshadern) and 195 CD patients and 210 controls in the
replication panel (from the LMUMunich Innenstadt Campus)]. In
addition, we analyzed 283 UC patients recruited from the IBD
center of the University Hospital Munich-Grosshadern. All
patients were of Caucasian origin.
Phenotypic data were collected blind to the results of the
genotypic data and consisted of demographic and clinical
parameters (behaviour and anatomic location of IBD, disease-
related complications, surgical or immunosuppressive therapy)
which were recorded by two senior gastroenterologists using
patient charts analysis and a detailed questionnaire including an
interview at time of enrolment. The diagnosis of CD and UC was
based on established guidelines based on endoscopic, radiological,
and histopathological parameters. The phenotypic classification of
CD patients was based on the Montreal classification [28],
including age at diagnosis (A), location (L), and behaviour (B) of
disease. In patients with UC, anatomic location was also assessed
in accordance to the Montreal classification based on the criteria
ulcerative proctitis (E1), left-sided UC (distal UC; E2), and
extensive UC (pancolitis; E3). Patients with indeterminate colitis
were excluded from the study. The demographic characteristics of
the study population are presented in table 1.
Sampling of Intestinal Biopsies from Patients with
Crohn’s Disease
In a subgroup of 27 CD patients, 75 intestinal biopsies from
inflamed and non-inflamed intestinal tissue were collected during
routine endoscopy. Written informed consent was obtained from
all patients prior to biopsy sampling. The study was approved by
the Ethics Committee of the Medical Faculty of the Ludwig-
Maximilians-University Munich. Detailed patient characteristics
are summarized in table 2.
DNA Extraction and Genotyping
For genotyping, genomic DNA was isolated from peripheral
blood leukocytes from all study participants using the DNA blood
mini kit (Qiagen, Hilden, Germany) following the manufacturer’s
instructions. The study participants were genotyped for seven
SNPs in the DMBT1 gene region.
The DMBT1 SNPs rs2981745, rs3013236 (corresponds to
p.Leu54Ser) and rs1052715 (p.Pro1707Pro) were investigated in
the study of Renner and co-workers [20]. Additionally, the tagging
SNPs rs2981778, rs11523871 (p.Pro42Thr), rs2981804 and
rs2277244 (p.His585Tyr) were selected from the data of the
International HapMap project covering the DMBT1 gene plus
10 kb flanking the centromeric and telomeric end of the gene,
respectively, and using a setting of r2 of 0.8 (Fig. 1A). Genotyping
was performed by PCR and melting curve analyses using a pair of
fluorescence resonance energy transfer (FRET) probes in a
LightCycler480 instrument. Detailed genotyping methodology
and the primers/probes used for genotyping are summarized in
the methods S1 and in tables S2 and S3. In addition, detailed
haplotype and subphenotype analyses were performed. Gene-gene
interactions (epistasis) of DMBT1 variants with variants in NOD2,
IL23R and IL27 were analyzed. Those genotype data were
available from previous studies [8,29,30,31,32,33]. IL-22 serum
protein levels were analyzed in previous study [34].
DMBT1 in Inflammatory Bowel Disesase
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Statistical Analysis
Single-marker allelic tests were performed with Pearson’s x2 test.
Student’s t-test was applied for quantitative variables. All tests were
two-tailed and P-values,0.05 were considered nominally significant.
Correction for multiple testing was performed using Bonferroni’s
method. We tested 7 DMBT SNPs for association with two
phenotypes (CD and UC status) resulting in a corrected P-value of
0.0036 (0.05/(2*7)). Empirical P-values were derived using
10,000,000 point-wise permutations. Odds ratios (OR) were calcu-
lated for the risk allele at each SNP. Data were evaluated by using the
SPSS 13.0 software (SPSS Inc., Chicago, IL, U.S.A.) and R-2.4.1.
(http://cran.r-project.org). Permutation-based P-values, interaction
P-values as well as haplotype and LD analysis were conducted using
PLINK v 1.07 (http://pngu.mgh.harvard.edu/˜purcell/plink/). We
ran a sliding window approach, varying the window size from 2 to 7
included markers and using the option ‘‘hap-logistic’’. Haplotype
omnibus P-values are based on jointly testing all H haplotype effects
at the specific position resulting in a H-1 degrees of freedom test. For
haplotype specific tests, individuals presenting with the specific
haplotype are compared to all other individuals.
Results
The Th17 Cytokine IL-22 Up-regulates STAT3-dependent
DMBT1 Expression in Intestinal Epithelial Cells
We and others have shown that IL-22 is an inducer of
antimicrobial peptides like defensins in IEC and other tissues
[35,36,37]. DMBT1 is an antibacterial scavenger receptor (9) and
we recently demonstrated that the STAT3-activating cytokine
IL-27 induces DMBT1 expression in IEC [23]. Given that IL-22 is
Table 1. Demographic and phenotypic characteristics of the IBD study population.
Crohn’s disease Ulcerative colitis Controls
n=818 n=283 n=972
Gender
Male (%) 46.0 53.0 63.8
Female (%) 54.0 47.0 36.2
Age (yrs)
Mean 6 SD 40.7613.3 43.8614.8 46.0610.3
Range 15–81 17–88 19–68
Body mass index
Mean 6 SD 23.064.2 23.964.5
Range 13–41 15–54
Age at diagnosis (yrs)
Mean 6 SD 27.9612.0 31.3613.7
Range 6–78 4–81
Disease duration (yrs)
Mean 6 SD 13.168.8 11.968.43
Range 0–46 1–50
Positive family history of IBD (%) 16.6 17.4
CD: Age at onset (n = 731)
#16 years (A1) 188 (25.7%)
17–40 years (A2) 461 (63.1%)
.40 years (A3) 82 (11.2%)
CD: Disease location (n = 777)
Terminal ileum (L1) 113 (14.5%)
Colon (L2) 99 (12.7%)
Ileocolon (L3) 555 (71.4%)
Upper GI (L4) 10 (1.3%)
CD: Behavior (n = 755)
Non-stricturing, non-penetrating (B1) 185 (24.5%)
Stricturing (B2) 210 (27.8%)
Penetrating (B3) 360 (47.7%)
UC: Disease location (UC) (n = 261)
Proctitis (E1) 24 (9.2%)
Left-sides colitis (E2) 97 (37.2%)
Pancolitis (E3) 140 (53.6%)
For each criterion according to the Montreal classification, the number of patients for which data were available, is given.
doi:10.1371/journal.pone.0077773.t001
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a known STAT3 activator [35], we hypothesized that IL-22 might
induce DMBT1 expression in IEC. To test this hypothesis, we
stimulated HT-29 and DLD-1 cells with 100 ng/ml IL-22 for 6
and 24 hours, respectively. Quantitative PCR revealed a
significant up-regulation of DMBT1 expression in both cell lines
(Fig. 2A). To determine the signaling pathways involved, we
transfected DLD-1 cells with siRNA against STAT3 or an
unspecific control siRNA prior to IL-22 stimulation. The IL-22-
induced DMBT1 expression was significantly reduced in cells with
knocked-down STAT3 expression (Fig. 2B).
Crohn’s Disease-associated IL23R Variants, which
Modulate IL-22 Expression, Influence Intestinal DMBT1
Expression in Patients with Crohn’s Disease
We have recently demonstrated that CD-associated variants in
IL23R modulate IL-22 expression. Higher IL-22 serum levels were
found in carriers of CD risk-associated IL23R SNPs and lower IL-
22 serum levels in carriers of CD-protective IL23R SNPs [34]
(summarized in table 3). Having shown that IL-22 induces
DMBT1 expression, we further analyzed these IL23R variants
regarding their association with DMBT1 expression. DMBT1
mRNA expression was determined by quantitative PCR in a total
of n = 75 inflamed and not inflamed intestinal biopsies collected
from 27 CD patients (for patient characteristics, see table 2).
DMBT1 expression in carriers of the minor allele (homozygous
and heterozygous) of the respective IL23R SNPs was divided by
the expression in homozygous carriers of the wild-type (WT) allele
(table 3, Fig. 3A). The odds ratios (ORs) for the analyzed IL23R
SNPs were available from a previous study [8]. In 5 out of 10
IL23R SNPs, there were significant differences (p,0.05) in
DMBT1 expression between carriers of the minor allele and
WT carriers (table 3). Similar to our previous results obtained for
Table 2. Characteristics of the CD patients from which intestinal biopsies were collected.
Patient
ID
Number of
biopsies Anatomic location of biopsy sampling*
DMBT1 rs2981804
genotype
Location
Montreal L
Behavior
Montreal B NOD2 mutation`
1 2 1x sigma (2), 1x colon (2) AA 1 3 1007fs +/+
2 2 1x colon (2), 1x colon (2) AA 3 3 G908R +/2
3 1 1x sigma (2) AA 3 1 2
4 5 3x colon (2), 1x sigma (2), 1x rectum (2) GA 3 2 2
5 2 1x sigma (2), 1x sigma (+) GA 3 2 2
6 5 1x colon (2), 4x colon (+) GA 3 2 R702W +/2, G908R +/2
7 2 1x rectum (2), 1x colon (+) GA 3 3 1007fs +/+
8 1 1x colon (2) GA 4 2 2
9 2 1x colon (2), 1x colon (+) GA 3 2 2
10 2 1x colon (2), 1x cecum (+) GA 3 1 2
11 2 2x colon (2) GA 3 3 R702W+/2, G908R+/2
12 2 1x colon (2), 1x ileocecal valve (+) GA 3 1 2
13 2 1x colon (2), 1x colon (+) GA 2 2 2
14 2 2x colon (2) GA 3 2 R702W+/2
15 1 1x colon (2) GG 3 2 2
16 1 1x cecum (2) GG 3 3 1007fs+/+
17 3 1x colon (2), 2x colon (+) GA 3 3 1007fs+/2
18 4 2x colon (2), 2x colon (+) AA 3 3 2
19 4 2x cecum (2), 2x cecum (+) AA 3 3 2
20 4 2x cecum (2), 2x terminal ileum (+) AA 3 1 2
21 3 2x colon (2), 1x colon (+) AA 3 2 1007fs+/+
22 4 2x cecum (2), 2x terminal ileum/ileocecal valve (+) AA 3 2 2
23 4 2x colon (2), 2x colon (+) AA 3 3 G908R+/2
24 4 2x colon (2), 2x terminal ileum (+) AA 3 3 G908R+/2
25 4 2x cecum (2), 2x terminal ileum (+) AA 3 2 2
26 3 2x colon (2), 1x colon (+) GA 3 1 2
27 4 2x cecum (2), 2x cecum (+) GA 3 3 2
total n =75 n=45 (2) AA: 11 (41%) L1:1 (4%) B1:5 (19%) R702W: 3 (11%)
n=30 (+) GA: 14 (52%) L2:1 (4%) B2:11 (41%) G908R: 3 (11%)
GG: 2 (7%) L3:24 (89%) B3:11 (41%) 1007fs: 7 (26%)
L4:1 (4%) NOD2 positive: 11
(41%)
*(2) = non-inflamed tissue; (+) = inflamed tissue;
`given are the three main NOD2 mutations R702W, G908R, 1007fs; 2=no mutation, +/2=heterozygous mutation, +/+ homozygous mutation.
doi:10.1371/journal.pone.0077773.t002
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IL-22 [34], there was a high correlation of OR regarding CD
susceptibility and DMBT expression ratio minor allele vs. WT (r
(OR/DMBT)=0.766) and between IL-22 and DMBT1 ratios minor
allele vs WT (r(DMBT/IL-22) =0.754). For all SNPs except
rs7517847, patients with risk-increasing IL23R variants had higher
DMBT1 expression when carrying the minor allele (OR.1 and
relative DMBT1 expression minor allele vs WT.1), while in
patients with IBD risk-decreasing IL23R variants, DMBT1
expression was lower in minor allele carriers compared to WT
carriers (OR,1 and relative expression minor vs. WT,1; table 3,
Fig. 3A). The correlation of OR and DMBT1 expression was
independent of the inflammation status of the analyzed biopsies
(figure S3).
Intestinal DMBT1 Expression is Increased in Active
Crohn’s Disease
Having demonstrated that DMBT1 is up-regulated by IL-22 and
IL-27 [23] and given the increased expression of IL-22 and IL-27 in
active IBD as shown by us and others [34,35,38], we next compared
DMBT1 mRNA expression levels in all inflamed (n= 30 biopsies)
and not inflamed (n= 45 biopsies) intestinal biopsies from the above
described 27 CD patients. DMBT1 expression was significantly
higher (16.6-fold) in inflamed colonic biopsies compared to not
inflamed regions (Fig. 3B, p= 7.661024).
Associations of DMBT1 Gene Variants and Haplotypes
with Crohn’s Disease in the German Population
Having shown that DMBT1 expression is associated with
disease activity in CD patients, we next aimed to determine
whether SNPs in the DMBT1 gene region might influence IBD
susceptibility. We genotyped 7 DMBT1 SNPs (rs2981745,
rs2981778, rs11523871 [p.Pro42Thr], rs3013236 [p.Leu54Ser],
rs2981804, rs2277244 [p.His585Tyr], rs1052715 [p.Pro1707Pro])
in a cohort of 818 CD patients and 972 controls (composed of two
separate cohorts: discovery panel: n = 623 cases/762 controls,
replication panel: n = 195 cases/210 controls). Allele frequencies of
all SNPs were in Hardy-Weinberg equilibrium (P-value.0.05
after Bonferroni correction for multiple testing; table S4). For all
Figure 1. Overview of the DMBT1 gene structure, SNP location and predicted transcription factor binding sites. (A) Exon-intron
structure of the DMBT1 gene and location of the analyzed DMBT1 SNPs. grey = untranslated region. (B) Potential binding sites of transcription factors
in the genomic region comprising SNP rs2981804. The binding sites on the genomic DNA are underlined; the polymorphic nucleotide is depicted in
bold underlined.
doi:10.1371/journal.pone.0077773.g001
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case-control panels, we demonstrated significant disease associa-
tions with certain DMBT1 SNPs (table 4, table S5). In the
combined CD sample panel (table 4), the most strongly CD-
associated SNP was rs2981804 (p = 3.061027, odds ratio (OR)
1.42, 95% confidence interval (CI) [1.24–1.63]), followed by SNP
rs2981745 (p = 7.761023, OR 1.21, 95% CI [1.05–1.39]; table 4).
In addition, the SNPs rs2981778, rs11523871 and rs3013236 (in
linkage disequilibrium (LD) with rs2981745, table S6) were weakly
associated with CD. Moreover, we genotyped a panel of 283 UC
patients (table S7). Both most strongly CD-associated DMBT1
SNPs were also associated with UC but rs2981745 displayed the
stronger association (rs2981745: p= 2.561024, OR 1.50, 95% CI
[1.24–1.82], rs2981804: p = 2.561023, OR 1.31 [1.08–1.58];
table S7).
To elucidate if the two most strongly IBD-associated SNPs
represent independent disease association, we conditioned associ-
ation analysis on the strongest signal, i.e. rs2981804 for CD and
rs2981745 for UC. Even after conditioning, effects for rs2981745
in CD (p= 1.061025) and rs2981804 in UC (p= 4.561024)
Figure 2. The Th17 cytokine IL-22 induces DMBT1 expression
in intestinal epithelial cells dependent on STAT3. (A) DMBT1
expression is induced by IL-22 in intestinal epithelial cells as determined
by quantitative PCR in HT-29 and DLD-1 cells stimulated with 100 ng/ml
IL-22 for 6 and 24 hours, respectively. Data are from five independent
experiments. DMBT1 expression in unstimulated cells was arbitrarily set
to 1.0 and expression in IL-22-stimulated cells was calculated
accordingly. *p,0.01 vs. unstimulated cells. (B) Silencing of STAT3
expression by siRNA transfection reduces IL-22-induced DMBT1
expression in DLD-1 cells. *p,0.01 vs. unstimulated; #p,0.05 vs.
control+IL-22.
doi:10.1371/journal.pone.0077773.g002
Figure 3. IL23R CD risk-increasing variants are associated with
higher DMBT1 expression in minor allele carriers and intestinal
inflammation increases DMBT expression levels in CD patients.
(A) Intestinal DMBT1 expression and IL23R genotypes were determined
in 75 biopsies from 27 CD patients. DMBT1 expression is presented as a
quotient derived from dividing expression in minor allele carriers of the
respective IL23R SNP by the expression in WT carriers. ORs for the
respective SNPs were available from a previous study [8]. (B) Intestinal
DMBT1 expression is significantly higher in inflamed colonic biopsies
(n = 30) compared to not inflamed regions (n = 45) from 27 CD patients.
Expression was normalized to b-actin in the respective samples. Each
dot represents one biopsy.
doi:10.1371/journal.pone.0077773.g003
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remained significant. Moreover, there was only weak LD between
both SNPs (r2 = 0.24, 0.18 and 0.17 for CD, UC, and controls,
respectively). All allele frequencies, P-values and ORs are shown in
tables 4 and tables S5–S7. Next, potential phenotypic conse-
quences of the two DMBT1 variants rs2981745 and rs2981804
were investigated using the Montreal classification of CD and UC
[28]. However, all statistical significant phenotypic associations
were rather weak and were not robust to multiple testing (table
S8–S10).
Table 3. IL23R gene variants modulate intestinal DMBT1 expression.
(1) (2) (3) (4) (5) (6) (7)
IL23R SNP
genotype (no of
biopsies)
Median
DMBT1
expression
P-value
minor
allele vs WT
DMBT1 expression
for IL23R minor
allele vs WT
IL-22 expression
for IL23R minor
allele vs WT#
OR regarding CD
suscep-tibility`
rs1004819 CC (n = 13) 0.00210 0.002 7.53 1.05 1.56
CT (n = 48) TT (n = 14) 0.01585
rs7517847 TT (n = 35) 0.01029 0.504 1.09 1.05 0.68
TG (n = 38) GG (n = 2) 0.01120
rs10489629 AA (n = 33) 0.01905 0.183 0.48 0.96 0.73
AG (n = 41) GG (n = 2) 0.00916
rs2201841 TT (n = 21) 0.00412 0.044 4.29 1.06 1.46
TC (n = 37) CC (n = 17) 0.01767
rs11465804 TT (n = 74) 0.01120 n.d. 0.45 0.81 0.53
TG (n = 1) GG (n = 0) 0.00505
rs11209026 GG (n = 74) 0.01120 n.d. 0.45 0.72 0.43
GA (n = 1) AA (n = 0) 0.00505
rs1343151 CC (n = 46) 0.01440 0.401 0.71 0.87 0.76
CT (n = 27) TT (n = 2) 0.01029
rs10889677 GG (n = 21) 0.00412 0.039 4.60 1.07 1.47
GA (n = 36) AA (n = 17) 0.01895
rs11209032 GG (n = 18) 0.00167 861024 11.32 1.26 1.43
GA (n = 40) AA (n = 17) 0.01895
rs1495965 AA (n = 5) 0.00661 0.033 1.69 1.10 1.33
AG (n = 50) GG (n = 20) 0.01120
The median DMBT1 mRNA expression was analyzed in a total of 75 biopsies from 27 CD patients for each IL23R variant. P values in column (4) are given for the
comparison of the DMBT1 expression of carriers of the IL23R minor allele (homozygous and heterozygous) compared to DMBT1 levels in IL23R wild-type carriers.
Column (5) summarizes the data from column (3) and represents the fold increase or decrease in DMBT1 expression in carriers of the IL23R minor allele (homozygous
and heterozygous) compared to DMBT1 levels in IL23R wild-type carriers for the respective IL23R SNP. The IL-22 serum levels of column 6 summarizes the results of a
previous study [34] while the odds ratios of column 7 represent the results of a previous detailed genotype analysis [8], in which all patients analyzed here participated.
The correlation coefficient between the DMBT1 quotient of column (5) and the ORs of column (7) is r = 0.766.
doi:10.1371/journal.pone.0077773.t003
Table 4. Association results of DMBT1 gene variants with CD in the combined discovery and replication panels.
Crohn’s disease: Combined panel n =818 Controls n =972
SNP Risk allele RAF empirical P-value OR [95% CI] RAF
rs2981745 T 0.372 7.761023 1.21 [1.05–1.39] 0.329
rs2981778 G 0.702 0.034 1.16 [1.01–1.35] 0.669
rs11523871= p.Pro42Thr A 0.703 0.038 1.16 [1.01–1.33] 0.671
rs3013236 = p.Leu54Ser T 0.708 0.020 1.19 [1.03–1.37] 0.670
rs2981804 A 0.563 3.061027 1.42 [1.24–1.63] 0.475
rs2277244 = p.His585Tyr C 0.976 0.086 1.41 [0.92–2.13] 0.966
rs1052715 = p.Pro1707Pro A 0.575 0.11 1.12 [0.98–1.28] 0.547
Risk allele frequencies (RAF), allelic test empirical P-values (1 degree of freedom), and odds ratios (OR, shown for the riskallele) with 95% confidence intervals (CI) are
depicted for both the CD and UC case-control panels. P-values,0.05 are highlighted in bold and P-values robust to multiple testing (P,0.0036) are highlighted in bold
italic. P-values are based on 10,000,000 permutations.
doi:10.1371/journal.pone.0077773.t004
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In order to investigate for potential disease associations with
certain DMBT1 haplotypes, we performed a detailed haplotype
analysis considering all possible haplotypes with a frequency of at
least 1% in the whole sample (table S11 and S12). In CD patients,
all haplotype groups analyzed were significantly associated with
the disease after correction for multiple testing including corrected
omnibus P-values of ,10210 in 60% of all analyzed haplotype
groups (table S11). The strongest association with CD was found
for a haplotype consisting of all seven analyzed SNPs (omnibus P-
value: 6.14610218, table 5 and table S11). This association was
mainly attributable to two haplotypes: CGATGCA and CGA-
TACA, which differ only in the rs2981804 allele (underlined). The
rare CGATGCA haplotype was significantly more common in
controls (haplotype frequency (HF) 0.13) than in CD patients (HF
0.02; p = 4.04610213; OR 0.25, 95% CI [0.17–0.36]). The more
abundant haplotype CGATACA was significantly more prevalent
in CD patients (HF: 0.34; p = 1.5361028, OR 1.54, 95% CI
[1.22–1.79] than in controls (HF 0.17).
Analysis for Epistasis between DMBT1 and NOD2, IL23R
and IL27 Gene Variants Regarding IBD Susceptibility
We then aimed to uncover potential epistasis of the DMBT1
variants rs2981745 and rs2981804 with other replicated IBD
susceptibility gene variants. We focused on NOD2, IL23R and
IL27, given that DMBT1 is a target gene of NOD2 [12] and IL-
23R [24]. Moreover, we recently demonstrated that IL23R
modulates the expression of the Th17 cytokine IL-22 [34]. IL-22
is an epithelial barrier-protective cytokine [35] that is a
transcriptional activator of DMBT1 expression as we demonstrat-
ed above. As IL-27 is a Th17 cell inhibiting cytokine [39], we also
included variants in the IL27 gene region for which we and others
recently demonstrated an association with IBD susceptibility
[32,40]. Moreover, we have recently shown that DMBT1 is also
a transcriptional target of IL-27 [23]. Data on NOD2, IL23R and
IL27 gene variants in our study population were available from
previous studies [8,32,33]. No evidence for epistasis between
DMBT1 variants and SNPs in NOD2 and the IL27 gene region was
found (table S13 and S14). For the IL23R SNP rs1004819, the
most strongly IBD-associated IL23R SNP in our cohort [8], there
was significant epistasis with the DMBT1 SNPs rs2981745
(p = 0.042) and rs2981804 (p = 0.031) in UC but not CD patients
(table S15). However, the identified statistical interaction was not
robust to multiple testing.
Allelic Variants of DMBT1 SNP rs2981804 Alter the DNA
Binding of the Transcription Factors CREB1 and ATF-2
As both most strongly IBD-associated DMBT1 SNPs rs2981745
and rs2981804 are located in non-coding regions of DMBT1
(rs2981745:59-untranslated region (UTR); rs2981804:6th intron,
Fig. 1A), we hypothesized that these SNPs might be located within
DNA binding sequences of nuclear proteins. We therefore
screened the respective genomic regions including the SNP and
10 bp upstream and downstream with the online tool TFsearch
[26]. For rs2981745, no significant differences in DNA binding
scores above the defined threshold were obtained for the two
alleles (data not shown). For rs2981804, the program predicted
differential binding of several transcription factors (table 6, Fig. 1B).
In EMSA experiments with probes containing either the IBD
risk allele A or the protective allele G of rs2981804 and the
surrounding genomic sequences, nuclear extracts from IEC lines
HT-29, DLD-1, HCT116 and SW480 bound strongly to the
probe containing the risk allele A. The probe with the IBD-
protective allele G showed clearly weaker protein binding (Fig. 4A).
To analyze which proteins were bound to the probes, antibodies
against phosphorylated cAMP responsive element binding protein
1 (CREB1) or activating transcription factor 2 (ATF-2) were
incubated together with the DNA binding reaction with nuclear
extracts from DLD-1 cells. For both transcription factors, higher
binding scores were predicted for the A allele in comparison to the
G allele (table 6). The addition of an ATF-2 or a CREB1 antibody
diminished but did not abolish DNA binding of protein to the
DMBT1 probe (Fig. 4B, lanes 3, 4) as well as did unlabelled
competitor probes with binding sequences for ATF-2 or CREB1
(Fig. 4B, lanes 5, 8). Addition of 50-fold excess of an unlabelled
DMBT1 probe with the A allele completely inhibited binding to
the labelled probe while a DMBT1 probe with the G allele had a
weaker effect (Fig. 4B, lanes 6, 7). Control reactions (Fig. 4B, lanes
9, 10) with a non-specific antibody or a non-specific DNA probe
Table 5. DMBT1 haplotypes are associated with CD.
Haplotype Crohn’s disease Controls
HF P-value OR [95% CI] HF
rs2981745–rs2981778–rs11523871–rs3013236–rs2981804–rs2277244–rs1052715 6.14610218
CGATGTG 0.01 9.8861022 0.62 [0.33–1.14] 0.02
CGATACG 0.13 7.3361023 0.77 [0.64–0.93] 0.23
CGATGCG 0.09 2.8161022 0.78 [0.63–0.97] 0.10
TACCGCA 0.15 1.1761021 0.85 [0.70–1.04] 0.20
TACCACA ,0.01 6.8561022 ,0.01 [,0.01–1.50] 0.03
TACCGCG 0.11 6.5761021 0.95 [0.74–1.21] 0.06
CGATGCA 0.02 4.04610213 0.25 [0.17–0.36] 0.13
CGATACA 0.34 1.5361028 1.54 [1.33–1.79] 0.17
TGATACG 0.03 2.9261025 29.40 [6.03–143.3] ,0.01
Haplotype frequencies (HF), P-values (including omnibus P-values), and odds ratios (OR) with 95% confidence intervals (CI) are given for the strongest haplotype-disease
association. Only the most significantly associated haplotypes are shown. The complete haplotype data can be found in the supplementary material. P-values for
individual haplotypes are presented for all haplotypes with a frequency of at least 1% in the whole sample and with an omnibus haplotype P-value ,0.05. Significant
P-values (,0.05) are highlighted in bold and significant P-values robust to multiple testing (P,2.561023 for omnibus P-values, P,4.861024 for detailed haplotype
P-values) are highlighted in bold italic.
doi:10.1371/journal.pone.0077773.t005
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which did not inhibit specific DNA-protein complex formation
demonstrated that two specific protein complexes with two distinct
sizes are bound to the DMBT1 probe (Fig. 4B, see arrows).
Next, we performed EMSA experiments using a labelled
CREB1 consensus probe. CREB1 protein binding was proven
by a CREB1-specific antibody (Fig. 4C, lane 4). Excess of
unlabelled DMBT1 probe was able to repress protein binding to
the CREB1 probe (Fig. 4C, lane 7). Moreover, on the same gel,
binding reactions with a labelled DMBT1 probe were included
(Fig. 4C, lanes 8–10). A more slowly migrating (and therefore
larger) protein complex bound to the DMBT1 probe that had
much stronger signal intensity (in comparison to the CREB1
probe) could be observed.
Then we transfected DLD-1 cells with a non-specific control
siRNA or siRNA against CREB1 and ATF-2 48 hours prior to
protein isolation. SiRNA-mediated down-regulation of CREB1
resulted in a nearly complete loss of protein binding to the
DMBT1 probe with the risk allele (Fig. 4D). Down-regulation of
ATF-2 also resulted in a slightly decreased protein binding to the
DMBT probe (Fig. 4D). Silencing of CREB1 and ATF-2 by the
respective siRNAs was confirmed by in western blot experiments
(Fig. S4A, B). Together, our data suggest that CREB1 and ATF-2
are essential parts of a larger multi-protein complex that binds
strongly to the DMBT1 probe containing the IBD risk allele of
rs2981804 but substantially less to the sequence with the protective
allele.
The Th17 Cytokine IL-22 Stimulates DMBT1 Expression in
Intestinal Epithelial Cells Dependent on the Transcription
Factors CREB1 and ATF-2
Next, we aimed to confirm that ATF2 and CREB1 are involved
in the transcriptional regulation of DMBT1. As we have shown
that IL-22 is an inducer of DMBT1 gene expression in IEC
(Fig. 2A), we next analyzed DMBT1 expression in IL-22-
stimulated DLD-1 cells in which expression of CREB1 or ATF-
2 was silenced by siRNA transfection. In control siRNA-
transfected cells, expression of DMBT1 was significantly up-
regulated by IL-22 after 6 hours of stimulation (p= 0.01; Fig. 5A).
In DLD-1 cells transfected with CREB1 siRNA, no increase in
DMBT expression was observed following IL-22 stimulation
(Fig. 5A). Silencing of ATF-2 prior to IL-22 stimulation had an
intermediate effect as IL-22-induced DMBT1 up-regulation was
still detectable but weaker than that of control siRNA-transfected
cells stimulated with IL-22 (Fig. 5A). Western blot experiments
with a DMBT1 antibody confirmed that the IL-22-induced
DMBT1 protein expression is inhibited by silencing of CREB1
or ATF-2 expression (Fig. 5B).
The Genomic Region Comprising DMBT1 SNP rs2981804
Differentially Influences Promoter Activity
To analyze whether the genomic region comprising the DMBT1
SNP rs2981804 directly influences gene transcription in vitro, we
cloned a PCR-amplified DMBT1 fragment with either the
rs2981804 A or G allele into two luciferase reporter vectors
containing either a minimal promoter (minP) or a strong SV40
promoter/enhancer as described in the methods and methods S1
section. The inserts were cloned either immediately upstream,
2 kb downstream or up- and downstream of the promoter-
luciferase gene region to analyze potential position-dependent
short-range and long-range effects on gene expression.
Luciferase assay in transfected DLD-1 cells revealed that in the
minP vector with low basal expression, the DMBT1 region
suppresses gene transcription, especially when cloned both up- and
downstream of the promoter-luciferase gene (Fig. 6A). When
cloned into a strong SV40 promoter-driven luciferase expression
vector, the DMBT1 fragment was able to further increase
luciferase gene expression (Fig. 6B). However, there were no
significant differences between the A and the G allele of
rs2981804. Similar results were obtained in HT-29 cells (data
not shown).
Intestinal DMBT1 Expression is Lower in Homozygous
Carriers of the DMBT1 rs2981804 IBD Risk Allele
To determine whether rs2981804 is associated with differential
DMBT1 expression in CD patients, DMBT1 mRNA expression
levels measured in human intestinal biopsies (Fig. 3B) were
subdivided according to the rs2981804 genotype [AA: n= 11
patients, 36 biopsies, 21 not inflamed, 15 inflamed; GA: n= 14
patients, 37 biopsies, 22 not inflamed, 15 inflamed; GG: n= 2
patients, 2 biopsies (both not inflamed)]. Overall, a trend towards
higher DMBT1 expression in carriers of the protective G allele
was observed (Fig. 7A, p = 0.06, AA vs. GA+GG). An inflamma-
tion-induced increase in DMBT1 expression was observed for
both rs2981804 AA and GA carriers (Fig. 7B). However, basal
DMBT1 expression was lower in homozygous carriers of the IBD
risk allele (AA) than in GA and GG carriers (p = 0.052 AA vs. GA,
p= 0.03 AA vs. GA+GG) (Fig. 7B). Similar results were obtained
Table 6. Overview of potential transcription factor binding sites in the genomic region harboring the DMBT SNP rs2981804.
Factor Consensus sequence#
Orientation
(+ strand)
position relative
to SNP (59 to 39)
Binding score
risk allele (A)
Binding score
protective allele (G)
CRE-BP1 (ATF-2) TTACGTAA forward 27 to 0 89.3 76.0
SRY AAACWAM forward 21 to+5 85.5 65.5
CREB1 TGACGTMA forward 27 to 0 84.2 77.7
HLF RTTACRYAAT reverse +1 to28 83.1 69.9
AML-1a TGCGGT reverse +5 to 0 82.7 66.4
Oct-1 NNNRTAATNANNN forward 27 to+5 79.3 70.0
E4BP4 NRTTAYGTAAYN forward 29 to+2 77.5 66.2
#Nucleotides in the consensus sequence that are identical to the genomic region surrounding SNP rs2981804 are underlined. The polymorphic nucleotide is depicted in
bold. The orientation of the binding site is given based on the sequence of the + strand.
Binding score threshold for the risk allele was set to 75.0. Only human transcription factors are listed. Nucleotide codes: M=A or C, N=A, C, G or T, R = A or G, W=A or T,
Y = C or T.
doi:10.1371/journal.pone.0077773.t006
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Figure 4. Variants in rs2981804 alter binding of the transcription factors CREB1 and ATF-2 to the respective genomic DNA
sequence. (A) EMSA analysis was performed with biotinylated probes and nuclear extracts from the intestinal epithelial cell lines HT-29 (lanes 2, 6),
DLD-1 (lanes 3, 7), SW480 (lanes 4, 8) and HCT116 (lanes 5, 9). A DNA probe containing the IBD risk allele A of rs2981804 is much stronger bound by
nuclear proteins than a probe with the G allele. Lane 1 contains the DNA probe only with no nuclear extract added. (B) Two specific protein
complexes binding to the DMBT1 probe can be detected. The addition of a ATF-2 (lane 3) or CREB1 (lane 4) antibody to the EMSA binding reactions
inhibit protein binding to the DMBT1 probe with the risk allele A while a non-specific isotype control antibody had no effect (lane 9). Addition of 50-
fold excess of unlabelled CREB1, ATF-2 or DMBT1 probe (G allele) reduced protein binding (lanes 5, 6, 8). A DMBT1 probe with the A allele completely
abolished protein binding (lane 7) while an unlabelled non-specific DNA probe did not inhibit DNA-protein complex formation confirming specificity
of binding (lane 10); ns = non-specific. (C) In EMSAs with a labelled CREB1 consensus probe (lanes 1–7), the addition of 50-fold excess of unlabelled
DMBT1 probe inhibited protein binding (lane 7) as well as did unlabelled CREB1 probe or a CREB1 antibody (lanes 4, 6). The protein complex bound
to a labelled DMBT1 probe (lanes 8–9) is migrating slower (and therefore larger) than that of the CREB1 probe. (D) Silencing of ATF-2 or CREB1
expression diminished protein binding to the DMBT1 probe. DLD-1 cells were transfected with siRNA against CREB1, ATF-2 or a non-specific control
siRNA 48 h prior to nuclear protein isolation. EMSA was performed as in Fig. 2A with a DMBT1 probe containing the A allele. While expression
silencing of CREB1 completely abolished protein binding to the DMBT1 probe, silencing of ATF-2 had a weaker but still detectable effect.
doi:10.1371/journal.pone.0077773.g004
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when NOD2 SNP carriers (see table 2) were excluded from analysis
(Fig. 7C).
Discussion
In this study, we performed a detailed functional analysis of the
DMBT1 gene. First, we investigated the effect of the Th17 cytokine
IL-22 on DMBT1 expression. In these detailed experiments, we
confirmed DMBT1 as a target gene of the cytokine IL-22. Our
results are supported by a recent study [22]. IL-22 is produced by
IL-23R-expressing Th17 cells [36] and we have recently shown
that variants in IL23R influencing the CD risk are associated with
differential IL-22 expression [34]. The same IL23R variants are
also associated with differential intestinal DMBT1 expression
suggesting a functional link between IL23R genotype, IL-22
expression and DMBT1 expression. A very recent study demon-
strated that DMBT1 expression in intestinal inflammation is
influenced by antibody treatment against IL-23R or IL-23 [24],
further supporting this hypothesis. Interestingly, we recently
demonstrated that the clinical response to infliximab, an anti-
TNF-a antibody used for treatment of IBD, is associated with
certain IL23R genotypes in UC patients [41].
In this study, we show that several previously not analyzed
DMBT1 SNPs and their haplotypes are associated with the
susceptibility to IBD. The two most strongly IBD-associated
DMBT1 SNPs were the non-coding SNPs rs2981745 and
rs2981804 for which the minor allele frequencies were significantly
higher in CD and UC patients compared to controls. Associations
remained significant even after conditioning the analysis on the
most strongly-associated SNP for each disease. Considering the
weak LD between both SNPs (r2 = 0.24, 0.18 and 0.17 for CD,
UC, and controls, respectively), our data suggest largely indepen-
dent associations with IBD susceptibility. We also demonstrated
for a large number of DMBT1 haplotypes highly significant
associations with CD and UC, with P-values as low as 10218. A
recent study demonstrated that a deletion variant in the repetitive
region of DMBT1 encoding the SRCR domains is associated with
CD [20]. Although it can not completely be excluded that the
SNPs analyzed in our study are in LD with this variant, it is rather
unlikely. SNP rs2277244 analyzed in our study is localized within
the repetitive SRCR genomic region and linkage analysis proved
that this SNP is not in LD with any other SNP examined here
(r2#0.02) suggesting that the SNPs analyzed in our study are
associated with IBD susceptibility independent of the SRCR
region. However, it has to be mentioned that our association
results need to be confirmed by replication in other large case-
control cohorts for both CD and UC. In recent GWAS studies and
meta-analyses, the DMBT1 gene region did not appear as major
risk factor for IBD [9,32,42,43]. One reason might be ethnic
differences between study population as it has been described for
other genes such as PHOX2B, NCF4 and FAM92B or DLG5
[44,45,46,47]. Another fact that might contribute to that lack is
the poor coverage of the DMBT1 gene region on the first available
GWAS chips, likely due to the many repetitive genomic regions
within the gene. Moreover, even though the most recent and so far
largest GWAS meta-analysis identified 163 IBD-associated vari-
ants, these genes explain only a small part of the IBD risk variation
Figure 5. IL-22-induced DMBT1 expression depends on the transcription factors CREB1 and ATF-2. (A) Silencing of CREB1 by siRNA
transfection completely abolished IL-22-induced DMBT1 mRNA expression while ATF2 silencing had a weaker negative effect. Data are from three
independent experiments. *p = 0.01 vs. control unstimulated. (B) DMBT1 protein expression is induced in IEC by treatment with IL-22 for 48 h.
Knockdown of ATF-2 or CREB1 expression prior to stimulation diminished IL-22-induced DMBT1 expression.
doi:10.1371/journal.pone.0077773.g005
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observed. Rare haplotypes conferring a highly significant IBD risk
(as we have observed in our study) might be missed.
Interestingly, a very recent study by Dinu et al. demonstrated
that a considerable number of genes or chromosomal regions
contribute to CD risk through SNP-SNP interactions [48]. Many
of those genes were not identified in recent GWAS analyses
including more than 20,000 patients and controls as these studies
analyzed only single SNP associations [48]. Remarkably, Dinu
et al. identified several so far unknown CD risk genes (FGFR2,
FOXI2, GLRX3) on chromosome 10 q26, surrounding the
chromosomal region that also harbours the DMBT1 gene [48].
Interestingly, both most strongly IBD-associated DMBT SNPs
in our study (rs2981745 and rs2981804) are located in non-coding
genomic regions, thereby not altering DMBT1 protein structure or
function. Therefore, we hypothesized that these SNPs might be
located within recognition sequences of transcription factors. For
the first time, we demonstrated that the transcription factors
CREB1 and ATF-2 differentially bind to DNA probes containing
either the IBD risk allele A or the protective G allele of SNP
rs2981804. Moreover, we show that CREB1 and ATF-2 are
involved in the transcriptional regulation of IL-22-induced
DMBT1 expression. We show in our study that the IBD risk
allele of rs2981804 is associated with a lower DMBT1 gene
expression in colonic tissue from CD patients identifying for the
Figure 6. The genomic region comprising DMBT1 SNP
rs2981804 differentially influences promoter activity. Luciferase
assays were performed in DLD-1 cells with DMBT1 inserts comprising
SNP rs2981804 A or G alleles. When cloned into a vector with weak
minimal promoter (A), the DMBT1 insert repressed luciferase expression
while together with a strong SV40 promoter, it increases gene
expression (B). *p,0.01; #p,0.001 vs. empty vector.
doi:10.1371/journal.pone.0077773.g006
Figure 7. The CD risk allele of DMBT1 SNP rs2981804 is
associated with lower colonic DMBT1 expression. (A) Colonic
DMBT1 mRNA expression was determined by quantitative PCR and was
normalized to b-actin expression in the respective samples (n = 75
biopsies from 27 CD patients). There was a trend towards higher DMBT1
expression in carriers of the G allele (GA+GG) in comparison to AA
carriers (p = 0.06). Each dot represents one biopsy and the black
horizontal bar is the median of each group. (B) When biopsies were
subdivided according to inflammation status, homozygous carriers of
the AA risk allele of SNP rs2981804 had lower basal and inflammation-
induced DMBT1 expression levels in comparison to carriers of the G
allele (p = 0.03 AA vs. GA+GG). (C) DMBT1 mRNA expression is
independent of NOD2 genotype status. DMBT1 mRNA expression was
determined in biopsies from CD patients irrespective of NOD2 genotype
(n = 75; black bars) or excluding biopsies from NOD2 SNP carriers (n = 45
NOD2 wild-type carriers; grey bars). Data are presented as median
DMBT1 expression in the respective groups. There were no significant
differences in DMBT1 expression between all biopsies and NOD2 wild-
type carriers for the different DMBT1 rs2981804 genotypes. n.s. = not
significant; `: no standard deviation is given for GG NOD2 wild-type
carriers as this group comprised only one biopsy.
doi:10.1371/journal.pone.0077773.g007
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first time a link between rs2981804 alleles and DMBT1 gene
expression. These results were independent of the NOD2 genotype.
Our luciferase assays revealed that the genomic region
comprising SNP rs2981804 can act either as a transcriptional
activator or repressor, depending on the promoter context. Given
that enhancers or repressors usually do not induce or repress gene
expression directly but interact with promoter-specific transcrip-
tion factors, such differences can be explained. Similar results have
been described for example for the c-myc enhancer [49]. There is
the possibility that the respective genomic region comprising
DMBT1 SNP rs2981804 not solely influences DMBT1 expression.
As enhancers/repressors can be located several hundred kb away
from genes which they regulate [50], the expression of other genes
located within this chromosomal region might be influenced as
well. Moreover, CREB1 and ATF-2 are transcription factor that
are ubiquitously expressed and are involved in the regulation of
many genes and cellular processes such as immunity, cell
proliferation, differentiation, and cell survival [51]. Therefore,
further analysis is necessary to determine whether the genomic
region comprising DMBT1 SNP rs2981804 influences expression
of other genes in vivo. Moreover, the differential influence of this
SNP on DMBT1 expression, especially in the presence of different
transcription factors and in the context of different cytokine
environments that have a strong influence on DMBT1 expression
[12,22,23], should be aims of future analyses.
In conclusion, we demonstrated novel significant associations of
DMBT1 variants and haplotypes with the susceptibility to CD.
Moreover, we provide for the first time functional evidence that
the non-coding DMBT1 SNP rs2981804 modifies the binding sites
for the transcription factors CREB1 and ATF-2. This DMBT1
SNP is associated with decreased overall DMBT1 expression in
the colon thereby probably contributing to increased CD
susceptibility. As DMBT1 encodes - like NOD2 - an antibacterial
pattern recognition receptor [11], our results support the
hypothesis that a dysregulated antibacterial response of the innate
immune system might contribute to the pathogenesis of CD.
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